NCT06924606 2026-02-06
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06751849 2024-12-30
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
The First Affiliated Hospital of Nanchang University
Phase 2 Recruiting
NCT06751901 2024-12-30
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
The First Affiliated Hospital of Nanchang University
Phase 2 Recruiting
NCT06752044 2024-12-30
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Phase NA Recruiting
NCT06752057 2024-12-30
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Phase NA Recruiting